In this episode. Ed and Kim talk with Ken Epstein, CCO & Co-Founder of Cannformatics, regarding this groundbreaking paper and what lies ahead for similar research. In spite of today’s cannabis challenges, Cannformatics, a San Francisco-based biotech startup, is conducting groundbreaking clinical studies to remove the confusion and stigma patients face when looking for medical cannabis to improve wellness. The work focuses on developing Cannabis-Responsive biomarkers that can be used to optimize medical cannabis treatments by providing patients and their physicians with data, similar to the data in a blood test, that shows how medical cannabis treatment is impacting the patient’s condition.